JPRN-UMIN000008439已完成未知
A Pivotal Study of TSB-002C for the Treatment of Paroxysmal Atrial Fibrillation - A Pivotal Study of TSB-002C for the Treatment of Paroxysmal Atrial Fibrillation
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •[Tentative Registration] (1) Subject has undergone previous LA ablation or surgical treatment for AF. (2) Subject is resistant or intolerant to all of pilsicainide, cibenzoline, propafenone, disopyramide, and flecainide. (3) Subject is in New York Heart Association (NYHA) Class III or IV. (4) Subject has a history of myocardial infarction (MI) or unstable angina within six months prior to enrollment. (5) Subject has a known history of severe ischemic heart disease or valvular disease. (6) Subject has left atrial appendage occlusion device. (7) Subject has severe pulmonary arterial hypertension. (8) Subject has an artificial heart valve. (9) Subject has a pacemaker and/or implantable cardiodefibrillator (ICD) and/or implantable loop recorder. (10) Subject has a history of cerebrovascular disease, including cerebral vascular accident (CVA) or transient ischemic attack (TIA) within six months prior to enrollment. (11) Subject has a known history of severe obstructive carotid artery disease. (12) Subject has an inferior vena cava (IVC) filter. (13) Subject has a known and unresolved deep vein thrombus (DVT). (14) Subject has significant renal failure. (15) Subject has a known history of a bleeding disorder related to hemophilia, leukemia, or lymphoma etc. (16) Subject cannot take any anticoagulant drug. (17) Subject has abnormal thyroid function and judged to be unsuitable for participation in the study by the investigator. (18) Subject has a documented allergy to iodine or iodine contrast media. (19)(20)(21)(22) -- (23) Subject has been judged to be unsuitable for participation in the study by the investigator for any other reason. [Formal Registration] (47) Subject has a left atrium > 50 mm. (48) Subject has a left ventricular ejection fraction (LVEF) < 35%. (49) Subject has a left atrial thrombus. (50) Subject has been judged to be unsuitable for participation in the study by the investigator for any other reason.
研究者
相似试验
已完成
不适用
A Pilot Study of TSB-002 for the Treatment of Atrial FibrillatioParoxysmal or persistent atrial fibrillationJPRN-UMIN000004409Toray Industries, Inc.30
招募中
2 期
In patients with previously untreated early stage triple negative breast cancer, how well does using Nivolumab or Nivolumab + Relatlimab before starting standard chemotherapy, OR starting treatment with Nivolumab and chemotherapy at the same time, help to reduce tumour size before surgery compared?Triple negative breast cancerCancer - BreastACTRN12619001308189Breast Cancer Trials162
尚未招募
1 期
Clinical observation on the treatment of type IIIB prostatitis by combining YiqiHuoXueTuoDu Formula with modified abdominal and anal retracting and lifting exerciseITMCTR2023000033Xiyuan Hospital, China Academy of Chinese Medical Sciences
尚未招募
Unknown
The effects of tecar therapy with biofeedback on the treatment of fecal incontinence in childreFecal incontinenceIRCT20140811018760N9Tabriz University of Medical Sciences56
已完成
2 期
ate Phase II Study of TS-142 in Patients with InsomniaInsomnia DisorderJPRN-jRCT2080225269Taisho Pharmaceutical Co., Ltd.160